RxDoctor Payments Data

Mohammad Shahin, MD

Internal Medicine · Corona, CANPI 1053393959

Payments from drug & device makers

$1,354in general payments, 2019–2025

Across 69 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$251
  • GSK$133
  • Novartis$127
  • Bayer$114
  • Amgen$111
  • Johnson & Johnson$102
  • plus $516 from 14 others

What the payments were for

  • Food & beverage$1,354100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,354 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$89,729
Medicare patients
207
Services billed
880

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban127$96,489
OzempicSemaglutide64$74,483
FarxigaDapagliflozin Propanediol48$53,081
JanuviaSitagliptin Phosphate35$37,992
EntrestoSacubitril/Valsartan30$26,160
JardianceEmpagliflozin24$25,028
Diclofenac Sodium92$20,009
LinzessLinaclotide28$19,012
XareltoRivaroxaban22$15,584
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,738
Atorvastatin Calcium590$9,436
Advair HfaFluticasone Propion/Salmeterol22$8,636
DapagliflozinDapagliflozin Propanediol11$8,110
Mesalamine13$6,975
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$6,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$96,489127 claims
Novo NordiskOzempic$251$74,48364 claims
AstraZenecaFarxiga$39$53,08148 claims
NovartisEntresto$127$26,16030 claims
AbbVieLinzess, Synthroid$16$21,05170 claims
Johnson & JohnsonXarelto$102$15,58422 claims
GSKTrelegy Ellipta$133$10,73812 claims
Lilly USA, LLCHumulin N$88$2,26715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →